The +RFID smart labels, which expands the +RFID portfolio of completely interoperable labelled pharmaceuticals, are said to be now fully compatible with all major RFID kit and tray systems present in the US
Fresenius Kabi’s Diprivan single-dose vial. (Credit: Business Wire)
Fresenius Kabi has rolled out its smart labels with embedded fully interoperable +RFID technology for Diprivan (Propofol) Injectable Emulsion, USP, 200 mg per 20 mL in single-dose vials, in the US.
Diprivan, Injectable Emulsion, USP is an intravenous general anaesthetic and sedation drug.
It is indicated for use in adults for combined sedation and regional anaesthesia, initiation and maintenance of Monitored Anaesthesia Care (MAC) sedation, and intensive care unit (ICU) sedation of intubated, mechanically ventilated patients.
The +RFID smart labels are said to be now fully compatible with all major RFID kit and tray systems in the US.
The launch expands the +RFID portfolio of completely interoperable labelled pharmaceuticals offered by Germany-based Fresenius Kabi.
By eliminating the need for manual medication tagging using radio-frequency identification (RFID) label technology, time is saved, and a safer, more effective medication inventory procedure is supported, the healthcare firm said.
Fresenius Kabi is said to be the first pharmaceutical company to use the GS1 EPC Tag Data Standard (TDS) to improve interoperability. GS1 Standards help ensure product and inventory information are accessible, accurate, and simple to understand.
Diprivan is claimed to be the first Fresenius Kabi product with RFID labelling, which was released in 2020 for use with various RFID kits and tray systems.
The medication is now approved for use with all RFID systems and may be ordered right away from the company or through wholesalers.
Diprivan +RFID has undergone testing by the Axia Institute of Michigan State University and certification by the ARC RFID lab of Auburn University to ensure that it meets the highest standards of performance and quality in addition to the company’s own testing.
Fresenius Kabi USA president and CEO John Ducker said: “We are dedicated to supporting our customers in the adoption of RFID technology that enhances patient care, improves efficiency and streamlines workflows for pharmacists.”
The healthcare company has also launched a newly labelled Vasopressin Injection, USP 20 units per 1 mL in single-dose vials with +RFID smart labels, expanding its growing line of goods that are interoperable with all significant RFID kit and tray systems.